DDInter463 DDInter1376
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Dacarbazine {u} (Compound) treats {v} (Disease) skin cancer
Dacarbazine {u} (Compound) binds {v} (Gene) POLA2
Dacarbazine {u} (Compound) upregulates {v} (Gene) CADM1
Dacarbazine {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Dacarbazine {u} (Compound) downregulates {v} (Gene) HMGCS1
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lomefloxacin
Dacarbazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Floxuridine
Dacarbazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brentuximab vedotin
Dacarbazine {u} may lead to a major life threatening interaction when taken with {v} Aldesleukin
Dacarbazine (Compound) treats skin cancer (Disease)
Dacarbazine (Compound) binds POLA2 (Gene)
Dacarbazine (Compound) upregulates CADM1 (Gene)
Dacarbazine (Compound) is included by Alkylating Activity (Pharmacologic Class)
Dacarbazine (Compound) downregulates HMGCS1 (Gene)
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Lomefloxacin
Dacarbazine may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin
Dacarbazine may lead to a major life threatening interaction when taken with Aldesleukin